Most Read Articles
12 Aug 2019
Treatment with nebivolol yields more favourable changes in 24-hour, intradialytic and daytime systolic and diastolic blood pressure variability in patients with intradialytic hypertension, a study has found.
Prof. Rafael R. Castillo, Dr. Hyo Seung Ahn, 20 Aug 2019
Major trials have demonstrated the benefits of beta-blockers in the treatment of hypertension.1 At a recent symposium held during the Asian Pacific Society of Cardiology 2019 Congress in Manila, Philippines, experts discussed the latest guidelines on hypertension treatment, with a focus on the role of the 3rd generation beta-blocker, nebivolol. The symposium was chaired by Dr Dante D. Morales, Clinical Associate Professor at the University of the Philippines College of Medicine, and featured renowned cardiologists Prof Rafael R. Castillo and Dr Hyo Seung Ahn.
Roshini Claire Anthony, 08 Sep 2020

In patients with locally advanced or metastatic ALK+ non-small cell lung cancer (NSCLC), treatment with the ALK tyrosine kinase inhibitor ensartinib led to superior progression-free survival (PFS) compared with crizotinib, according to interim results of the phase III eXalt3* trial.

Dermatitis (Patient Counselling Guide)

05 Jun 2020
Dermatitis, eczema, and rash are related terms which refer to skin inflammation characterized by an itchy pink or red rash. There are several forms of dermatitis commonly experienced by many as discussed below. It can also be acute or chronic depending on the duration of the condition. In acute dermatitis, red rash evolves rapidly oftentimes blistered and swollen. Chronic dermatitis is characterized by a dark, thickened (lichenified) and scratched skin which has been present for a long time.

* Click below to view the Patient Counselling Guide in Thai
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Thailand digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
12 Aug 2019
Treatment with nebivolol yields more favourable changes in 24-hour, intradialytic and daytime systolic and diastolic blood pressure variability in patients with intradialytic hypertension, a study has found.
Prof. Rafael R. Castillo, Dr. Hyo Seung Ahn, 20 Aug 2019
Major trials have demonstrated the benefits of beta-blockers in the treatment of hypertension.1 At a recent symposium held during the Asian Pacific Society of Cardiology 2019 Congress in Manila, Philippines, experts discussed the latest guidelines on hypertension treatment, with a focus on the role of the 3rd generation beta-blocker, nebivolol. The symposium was chaired by Dr Dante D. Morales, Clinical Associate Professor at the University of the Philippines College of Medicine, and featured renowned cardiologists Prof Rafael R. Castillo and Dr Hyo Seung Ahn.
Roshini Claire Anthony, 08 Sep 2020

In patients with locally advanced or metastatic ALK+ non-small cell lung cancer (NSCLC), treatment with the ALK tyrosine kinase inhibitor ensartinib led to superior progression-free survival (PFS) compared with crizotinib, according to interim results of the phase III eXalt3* trial.